GLP-1, GIP and Glucagon Receptors: Understanding Incretin and Metabolic Research
The short answer
GLP-1, GIP and glucagon are naturally occurring peptide hormones involved in metabolic regulation. Each acts through its own receptor. Researchers have studied these systems individually and have also designed molecules intended to activate more than one receptor.
The evidence is not uniform across the field. GLP-1 receptor biology and several pharmaceutical GLP-1 receptor agonists have been studied extensively in people. Dual- and triple-receptor strategies are newer, and the evidence depends on the exact molecule, study design, population and stage of development. Knowing that two materials interact with the same receptor does not make them interchangeable.
What is a receptor pathway?
A receptor is a protein that can respond when a compatible signalling molecule binds to it. Binding may begin a series of events inside a cell. The outcome depends on where the receptor is expressed, the properties of the signalling molecule, exposure, competing signals and the biological system being studied.
A receptor mechanism is therefore one layer of evidence. It can help explain why researchers investigate a molecule, but receptor activation alone does not establish a clinical outcome, long-term safety or equivalence between different compounds.
GLP-1 receptor research
GLP-1 is released from the gastrointestinal system after food intake and participates in glucose-dependent insulin secretion, glucagon regulation, gastric function and appetite-related signalling. Human experiments and randomized clinical trials have shown that pharmaceutical GLP-1 receptor agonists can affect appetite, energy intake, glucose measures and body weight in defined populations.
Those clinical findings apply to the specific authorized or investigational drug, formulation, manufacturing standard and population studied. They should not be transferred automatically to a research material simply because it is described as acting at the GLP-1 receptor.
GIP receptor research
GIP is another incretin hormone released after nutrient intake. Its receptor is found in several tissues, and its role in glucose regulation and energy balance has been studied in laboratory models and people. The development of dual GIP/GLP-1 receptor agonists demonstrated that combined receptor pharmacology can produce effects that cannot be predicted by discussing either receptor in isolation.
Researchers are still investigating how much of a multi-receptor molecule’s observed effect comes from each receptor and how receptor activity changes with molecular design, exposure and the characteristics of the study population.
Glucagon receptor research
Glucagon is often introduced only as a hormone that raises blood glucose, but its biology is broader. Glucagon receptor signalling also affects hepatic metabolism and energy expenditure. That creates both scientific interest and complexity: increasing glucagon-receptor activity could contribute to energy-balance effects while also creating glucose-related considerations.
For this reason, a balanced multi-receptor molecule is not simply three familiar actions added together. Researchers must measure the activity of the complete molecule and evaluate both intended and unintended outcomes.
Single, dual and triple agonism
A single-receptor agonist is designed primarily around one receptor. Dual and triple agonists are designed to engage two or three receptor systems. The terms describe intended pharmacology; they do not state how strongly each receptor is activated in a living system or guarantee a particular result.
Preclinical experiments can compare receptor activity and investigate mechanisms. Clinical trials can test outcomes in people. A promising animal result may provide a rationale for human research, but it does not predict the magnitude of a human response or establish safety.
Body-weight research and careful interpretation
Body-weight outcomes have been studied clinically with several GLP-1-based pharmaceutical agents. These trials have produced meaningful evidence in specific patient populations, but they do not show that every molecule associated with GLP-1, GIP or glucagon signalling will have the same effect.
When reading a weight-related claim, ask which molecule was tested, whether the study involved cells, animals or people, how participants were selected, what comparator was used, how long follow-up lasted, what proportion discontinued and whether the findings have been reproduced.
Key points
- GLP-1, GIP and glucagon act through different receptors.
- Receptor activation is a mechanism, not proof of a whole-person outcome.
- Clinical evidence for one pharmaceutical cannot be assigned to another compound or research material.
- Dual and triple agonists must be evaluated as complete molecules.
- Body-weight findings require the exact study population, design, duration and limitations.
What this article does not establish
This article does not establish the safety, effectiveness, quality or regulatory status of an AURAPEP product and does not recommend any compound for weight management or another personal use.
Primary references
- Blundell J, et al. Effects of semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017. https://pubmed.ncbi.nlm.nih.gov/28266779/
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/30473097/
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35985340/